In addition, a prospective observational study of dyslipidemic patients with diabetes or hyperglycemia showed that bezafibrate significantly reduces haemoglobin A1c (HbA1c) concentration as a function of baseline HbA1c levels, regardless of concurrent use of antidiabetic drugs.
Observational research on dyslipidemic individuals with diabetes or high blood sugar revealed that bezafibrate effectively lowers HbA1c levels in patients, regardless of whether they were taking other diabetes medications.